Most notably, presence of the isocitrate dehydrogenase 1 (IDH1) mutation was shown to be associated with WHO grade II/III gliomas and secondary GBM as well as a significantly longer progression-free and overall survival [7–10]. The gene discussed is IDH1; the disease is glioma.